PitchSend

Investor Presentaiton

EBITDA Trend In INR Billion Net 39 57 80 Sales 112 160 273 % of Net Sales 21% 19% 17% 27% 26% 25% 13% 14% 15% 12% 14% 16% 24% 25% 24% 27% 26% 30% 44% 44% 41% 34% 34% 29% FY10 FY11 FY12 FY13 FY14 FY15* EBITDA Other Expenditure Personnel Costs Material Costs FY10 - FY14 numbers exclude Ranbaxy financials * FY15 numbers include the impact of Ranbaxy merger © Sun Pharmaceutical Industries Limited. All Rights Reserved. SUN PHARMA Key drivers include Taro, generic Doxil, Doxycycline & other low competition products in US Impact of Ranbaxy acquisition, & temporary supply constraints at Halol facility 47

View entire presentation